Literature DB >> 23624779

High plasma-GFAP levels in metastatic myxopapillary ependymoma.

Ayseguel Ilhan-Mutlu1, Anna S Berghoff, Julia Furtner, Karin Dieckmann, Irene Slavc, Thomas Czech, Christine Marosi, Ludwig Wagner, Matthias Preusser.   

Abstract

Myxopapillary ependymoma (MPE) is a rare tumor of the distal spinal cord. Despite benign histopathology, local recurrences occur in ~30 % of patients and distant metastases have been described in few cases. MPE tumor cells typically express glial fibrillary acidic protein (GFAP), which could be released to the circulation. In this current report, we investigated circulating plasma-GFAP in a series of MPE patients. We analyzed circulating plasma-GFAP using a commercially available ELISA kit in 3 patients with completely resected MPE, 1 patient with locally advanced MPE and 2 patients with pleuropulmonary metastases of MPE. As controls we used blood samples of age and gender-matched healthy volunteers (n = 3), 6 glioblastoma patients with known plasma-GFAP status (positive for 3 and negative for 3 patients) and 3 brain metastases patients with known plasma-GFAP negativity. We found very high concentrations of plasma-GFAP in two MPE patients with pleuropulmonary metastases, while in none of the other MPE patients circulating plasma-GFAP was detectable. Circulating GFAP could be useful as marker for early detection or follow-up of distant metastases in MPE patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624779     DOI: 10.1007/s11060-013-1134-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  Myxopapillary ependymoma with pleuropulmonary metastases and high plasma glial fibrillary acidic protein levels.

Authors:  Aysegül Ilhan; Julia Furtner; Peter Birner; Karl Rössler; Christine Marosi; Matthias Preusser
Journal:  J Clin Oncol       Date:  2011-09-06       Impact factor: 44.544

2.  Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke.

Authors:  C Foerch; I Curdt; B Yan; F Dvorak; M Hermans; J Berkefeld; A Raabe; T Neumann-Haefelin; H Steinmetz; M Sitzer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-20       Impact factor: 10.154

Review 3.  Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000).

Authors:  L F Eng; R S Ghirnikar; Y L Lee
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

Review 4.  Subcutaneous sacrococcygeal myxopapillary ependymoma.

Authors:  I Ilhan; S Berberoglu; L Kutluay; H A Maden
Journal:  Med Pediatr Oncol       Date:  1998-02

5.  Exploratory investigation of eight circulating plasma markers in brain tumor patients.

Authors:  Aysegul Ilhan-Mutlu; Ludwig Wagner; Georg Widhalm; Adelheid Wöhrer; Sophie Bartsch; Thomas Czech; Harald Heinzl; Fritz Leutmezer; Daniela Prayer; Christine Marosi; Wolfgang Base; Matthias Preusser
Journal:  Neurosurg Rev       Date:  2012-07-05       Impact factor: 3.042

6.  Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas.

Authors:  Hatim Husain; William Savage; Stuart A Grossman; Xiaobu Ye; Peter C Burger; Allen Everett; Chetan Bettegowda; Luis A Diaz; Cherie Blair; Katharine E Romans; Matthias Holdhoff
Journal:  J Neurooncol       Date:  2012-04-11       Impact factor: 4.130

7.  Serum GFAP is a diagnostic marker for glioblastoma multiforme.

Authors:  C S Jung; C Foerch; A Schänzer; A Heck; K H Plate; V Seifert; H Steinmetz; A Raabe; M Sitzer
Journal:  Brain       Date:  2007-11-12       Impact factor: 13.501

8.  Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction.

Authors:  A Aurell; L E Rosengren; B Karlsson; J E Olsson; V Zbornikova; K G Haglid
Journal:  Stroke       Date:  1991-10       Impact factor: 7.914

9.  The results of surgery, with or without radiotherapy, for primary spinal myxopapillary ependymoma: a retrospective study from the rare cancer network.

Authors:  Alessia Pica; Robert Miller; Salvador Villà; Sidney P Kadish; Yavuz Anacak; Huda Abusaris; Gokhan Ozyigit; Brigitta G Baumert; Renata Zaucha; Guy Haller; Damien C Weber
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-02-26       Impact factor: 7.038

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088

View more
  3 in total

1.  Microwave-accelerated bioassay technique for rapid and quantitative detection of biological and environmental samples.

Authors:  Muzaffer Mohammed; Maleeha F Syed; Kadir Aslan
Journal:  Biosens Bioelectron       Date:  2015-08-31       Impact factor: 10.618

2.  Evaluation of eight plasma proteins as candidate blood-based biomarkers for malignant gliomas.

Authors:  Ryan P Lange; Allen Everett; Pratima Dulloor; Frederick K Korley; Chetan Bettegowda; Cherie Blair; Stuart A Grossman; Matthias Holdhoff
Journal:  Cancer Invest       Date:  2014-07-14       Impact factor: 2.176

Review 3.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders.

Authors:  Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2022-02-03       Impact factor: 44.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.